Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis

Overview

Journal Clin Med Insights Oncol

Publisher Sage Publications

Specialty Oncology

Date 2024 Dec 30

PMID 39734512

Authors

Youran Dai

Tianyin Ruan

Wenhui Yang

Shan Liu

Jiahao Chen

Yingying Fang

Qiushuang Li

Affiliations

Soon will be listed here.

Abstract

Background: Triple negative breast cancer (TNBC) is a deadly subtype of breast cancer with limited treatment options. Currently, programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors have become the first choice for breast cancer immunotherapies. Despite paclitaxel being considered a cornerstone drug in breast cancer treatment, the effectiveness, safety, and optimal drug selection for its combination with PD-1/PD-L1 inhibitors remain uncertain.

Methods: We conducted a systematic review and network meta-analysis, performing a comprehensive literature search across PubMed, Embase, and the Cochrane Library from the inception of each database through May 18, 2024. Selected trials were those that assessed the efficacy and safety of paclitaxel-based PD-1/PD-L1 therapies for the treatment of TNBC. The primary endpoint assessed was overall survival (OS), while secondary outcomes included progression-free survival (PFS), adverse events (AEs), overall response rate (ORR), and Pathological complete response (pCR). This study is registered in PROSPERO under registration number CRD42023429651.

Results: A total of 8 RCTs meeting our eligibility criteria were included, involving 4626 patients who received either Paclitaxel (Paclitaxel-placebo/chemotherapy) or a combination of durvalumab, pembrolizumab, atezolizumab, toripalimab with paclitaxel. The pooled results demonstrated that Durvalumab combined with Paclitaxel significantly reduced the hazard ratio for OS (surface under the cumulative ranking [SUCRA]: 91.05%) and PFS compared with Paclitaxel alone (SUCRA: 83.52%). Additionally, Durvalumab plus Paclitaxel significantly improved the ORR compared with Paclitaxel (odds ratio [OR]: 2.30; 95% credible interval [CrI]: 1.10-5.20). For safety outcomes, Atezolizumab plus Paclitaxel showed a favorable profile in AEs, with no significant differences observed between groups. In the pCR study, Pembrolizumab plus Paclitaxel was the most effective treatment option (SUCRA: 81.85%).

Conclusions: When combined with paclitaxel, PD-1/PD-L1 inhibitors exhibit a favorable survival benefit. The combination of Durvalumab and paclitaxel represents the optimal treatment option. In the future, attention should be paid to the TNBC subtypes and drug dosage, as these factors may help to design personalized TNBC treatment programs.

References

Hasegawa T, Ariyasu R, Tanaka H, Saito R, Kawashima Y, Horiike A . Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02). Cancer Chemother Pharmacol. 2023; 92(1):29-37. DOI: 10.1007/s00280-023-04547-2. View

Li C, Zhao S, Zheng Y, Han Y, Chen X, Cheng Z . Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2020; 144:232-241. DOI: 10.1016/j.ejca.2020.11.039. View

Chen H, Lu W, Zhang Y, Zhu X, Zhou J, Chen Y . A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. Cancer Med. 2018; 8(1):383-399. PMC: 6346255. DOI: 10.1002/cam4.1892. View

Cortes J, Andre F, Goncalves A, Kummel S, Martin M, Schmid P . IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncol. 2019; 15(17):1951-1961. DOI: 10.2217/fon-2019-0059. View

Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L . Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017; 6(1):79. PMC: 5389085. DOI: 10.1186/s13643-017-0473-z. View

Cimino-Mathews A, Thompson E, Taube J, Ye X, Lu Y, Meeker A . PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2015; 47(1):52-63. PMC: 4778421. DOI: 10.1016/j.humpath.2015.09.003. View

Huang W, Ran R, Shao B, Li H . Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019; 178(1):17-33. DOI: 10.1007/s10549-019-05371-0. View

Wills S, Hochmuth L, Bauer Jr K, Deshmukh R . Durvalumab: a newly approved checkpoint inhibitor for the treatment of urothelial carcinoma. Curr Probl Cancer. 2018; 43(3):181-194. DOI: 10.1016/j.currproblcancer.2018.08.010. View

Mayer I, Abramson V, Lehmann B, Pietenpol J . New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014; 20(4):782-90. PMC: 3962777. DOI: 10.1158/1078-0432.CCR-13-0583. View

10.

Pusztai L, Yau C, Wolf D, Han H, Du L, Wallace A . Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021; 39(7):989-998.e5. PMC: 11064785. DOI: 10.1016/j.ccell.2021.05.009. View

11.

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

12.

Disis M, Adams S, Bajpai J, Butler M, Curiel T, Dodt S . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. J Immunother Cancer. 2023; 11(6). PMC: 10277149. DOI: 10.1136/jitc-2022-006624. View

13.

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

14.

Centanni M, Moes D, Troconiz I, Ciccolini J, van Hasselt J . Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019; 58(7):835-857. PMC: 6584248. DOI: 10.1007/s40262-019-00748-2. View

15.

Lumley T . Network meta-analysis for indirect treatment comparisons. Stat Med. 2002; 21(16):2313-24. DOI: 10.1002/sim.1201. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Won K, Spruck C . Triple‑negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol. 2020; 57(6):1245-1261. PMC: 7646583. DOI: 10.3892/ijo.2020.5135. View

18.

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J . Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022; 33(11):1149-1158. DOI: 10.1016/j.annonc.2022.07.1940. View

19.

Akinleye A, Rasool Z . Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019; 12(1):92. PMC: 6729004. DOI: 10.1186/s13045-019-0779-5. View

20.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View